Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
RNLX

RNLX - Renalytix AI plc Stock Price, Fair Value and News

$3.98 
Market Closed as of 09 Feb 2026, 04:00 pm ET

Price Targets

RNLX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RNLX Price Action

Last 7 days

-10.6%

RNLX RSI Chart

RNLX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RNLX Valuation

Market Cap

660.4M

Price/Earnings (Trailing)

-23.56

Price/Sales (Trailing)

280.78

EV/EBITDA

-23.78

Price/Free Cashflow

-27.02

RNLX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

RNLX Fundamentals

RNLX Revenue

RNLX Earnings

RNLX Profitability

Free Cashflow Yield

-3.7%

RNLX Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20242.2M2.3M2.4M0
20233.7M3.4M2.9M2.4M
20222.6M3.0M3.5M3.8M
202101.5M1.9M2.2M
20200000
Get all data in R, Python etc through our Historical Stock Data APIs

About Renalytix AI plc

RNLX
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.
 CEO
 WEBSITEhttps://renalytix.com
 SECTORHealthcare
 INDUSTRYHealth Information Services
 EMPLOYEES102

Renalytix AI plc Frequently Asked Questions

RNLX is the stock ticker symbol of Renalytix AI plc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Feb 09 2026, market cap of Renalytix AI plc is 660.38 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Feb 09 2026, RNLX's PE ratio (Price to Earnings) is -23.56 and Price to Sales (PS) ratio is 280.78. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RNLX PE ratio will change depending on the future growth rate expectations of investors.